Design, synthesis, biological evaluation and DFT calculation of novel spirocyclic butenolide derivatives containing rhodanine as potential antifungal inhibitors
Pest Management Science · 2025
DOI: 10.1002/ps.8971 ↗At a glance
Journal article in Pest Management Science, 2025. Written by Tingting Zhang and 6 co-authors. Institution: Innovation Center of Pesticide Research, Department of Applied Chemistry, College of Science, China Agricultural University, Beijing, China. Major MEDLINE topics: Rhodanine, Fungicides, Industrial, 4-Butyrolactone, Antifungal Agents. 55 references. Funded by: National Key Research and Development Program of China, the National Natural Science Foundation of China.
Abstract (original language)
BACKGROUND The problem of resistance for fungicides has emerged in various plant pathogens and is a serious threat to crop protection. There is an urgent requirement to develop new fungicides to address the resistance issue. RESULTS Novel spirocyclic butenolides containing rhodanine scaffold were designed and synthesized, their structures were characterized with hyudrogen ( 1 H) and carbon ( 13 C) nuclear magnetic resonance (NMR) and high‐resolution electrospray ionization–mass spectrometry (HR‐ESI‐MS). The in vitro antifungal activities were evaluated against five phytopathogens. These results demonstrated that most compounds exhibited remarkable antifungal activities. The median effective concentration (EC 50 ) data of compound 4a were 0.39 μg mL ‒1 ( Fusarium graminearum ), 0.97 μg mL ‒1 ( F. fujikuroi ), 0.98 μg mL ‒1 ( Colletotrichum gloeosporioides ), 0.89 μg mL ‒1 ( F. oxysporum vasinfectum ) and 0.84 μg mL ‒1 ( F. oxysporum niveum ), respectively. Compound 4c was the best active compound against C. gloeosporioides with an EC 50 of 0.27 μg mL ‒1 . The in vivo antifungal activities of 4a and 4c were evaluated against C. gloeosporioides , the protective efficacies were 50.2%, 52.7% at Day 5 at a concentration of 100 μg/mL. The DFT results indicated that the two configuration isomers of target compounds have similar energies (Δ E = 0.45 kcal mol ‒1 ), which rationalized that two configuration isomers were coexistence in a similar ratio. The results of scanning and transmission electron microscopic observation indicated that treatment with compound 4a and phenamacril had similar effects on the morphology and ultrastructure of mycelia. CONCLUSION The excellent in vitro and in vivo inhibitory activities of novel spirocyclic butenolides containing rhodanine against F. graminearum, F. oxysporum and C. gloeosporioides were reported, and they could be used as the potential lead compounds. © 2025 Society of Chemical Industry.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Innovation Center of Pesticide Research, Department of Applied Chemistry, College of Science, China Agricultural University, Beijing, China.
- Department of Plant Pathology, College of Plant Protection, China Agricultural University, Beijing, China.
ORCID profiles: Guoen Cui, Haoyun Ma, Mingan Wang
Funding
- National Key Research and Development Program of China
- the National Natural Science Foundation of China
Cite
APA
Zhang, T., Cui, G., An, X., Ma, H., Jiang, J., Liu, X., & Wang, M. (2025). Design, synthesis, biological evaluation and DFT calculation of novel spirocyclic butenolide derivatives containing rhodanine as potential antifungal inhibitors. Pest Management Science. https://doi.org/10.1002/ps.8971
Vancouver
Zhang T, Cui G, An X, Ma H, Jiang J, Liu X, et al. Design, synthesis, biological evaluation and DFT calculation of novel spirocyclic butenolide derivatives containing rhodanine as potential antifungal inhibitors. Pest Management Science. 2025. doi:10.1002/ps.8971
BibTeX
@article{Zhang2025,
author = {Zhang, Tingting and Cui, Guoen and An, Xinkun and Ma, Haoyun and Jiang, Jiazhen and Liu, Xili and Wang, Mingan},
title = {Design, synthesis, biological evaluation and DFT calculation of novel spirocyclic butenolide derivatives containing rhodanine as potential antifungal inhibitors},
journal = {Pest Management Science},
year = {2025},
doi = {10.1002/ps.8971}
}
EUVIMED